(Q38026918)

27 August 2017

title

Cardiovascular effects of GLP-1 and GLP-1-based therapies: implications for the cardiovascular continuum in diabetes? (English)

1 reference

27 August 2017

M Burgmaier

1

1 reference

27 August 2017

C Heinrich

series ordinal

2

1 reference

27 August 2017

N Marx

series ordinal

3

1 reference

27 August 2017

language of work or name

1 reference

1 March 2013

1 reference

27 August 2017

1 reference

27 August 2017

volume

30

1 reference

27 August 2017

issue

3

1 reference

27 August 2017

page(s)

289-299

1 reference

Heart disease and stroke statistics--2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2012.03746.X

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2012.03746.X

Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2012.03746.X

10-year follow-up of intensive glucose control in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2012.03746.X

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2012.03746.X

Effects of intensive glucose lowering in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2012.03746.X

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2012.03746.X

Glucose control and vascular complications in veterans with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2012.03746.X

Human glucagon-like peptides 1 and 2 activate rat brain adenylate cyclase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2012.03746.X

Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2012.03746.X

Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2012.03746.X

Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2012.03746.X

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2012.03746.X

Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2012.03746.X

Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2012.03746.X

Prevalence of insulin resistance in metabolic disorders: the Bruneck Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2012.03746.X

Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2012.03746.X

Diabetes Ten City Challenge: final economic and clinical results

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2012.03746.X

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2012.03746.X

Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2012.03746.X

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2012.03746.X

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2012.03746.X

Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2012.03746.X

Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2012.03746.X

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2012.03746.X

Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2012.03746.X

Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2012.03746.X

Improvement of postprandial endothelial function after a single dose of exenatide in individuals with impaired glucose tolerance and recent-onset type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2012.03746.X

Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2012.03746.X

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2012.03746.X

Role of diabetes in congestive heart failure: the Framingham study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2012.03746.X

Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2012.03746.X

Vasorelaxant effect of glucagon-like peptide-(7-36)amide and amylin on the pulmonary circulation of the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2012.03746.X

Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2012.03746.X

Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2012.03746.X

Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2012.03746.X

10.1111/J.1464-5491.2012.03746.X

21 January 2018

Identifiers

DOI

1 reference

27 August 2017

1 reference